Introduction
Methods
Study design and population
Definitions
Statistical analysis
Results
Clinical and pathological characteristics of patients with nephrotic syndrome
Variables | NS group (n = 59) | non-NS group (n = 954) | P Value |
---|---|---|---|
Age (y) | 42.69 ± 14.96 | 37.78 ± 12.17 | 0.003 |
Gender (M/F) | 26/33 | 450/504 | 0.643 |
SBP (mm Hg) | 124 ± 14 | 125 ± 13 | 0.84 |
HB (g/l) | 120.69 ± 24.73 | 130.24 ± 21.48 | < 0.001 |
Scr (umol/l) | 127.34 ± 114.88 | 90.89 ± 55.48 | < 0.001 |
eGFR (ml/min.1.73m2) | 68.52 ± 33.04 | 93.11 ± 31.08 | < 0.001 |
Proteinuria (g/24 h, median,IQR) | 5160 (4100 ~ 6444) | 1134 (602 ~ 2106) | < 0.001 |
Uric acid (umol/L) | 400.52 ± 107.04 | 361.40 ± 106.45 | 0.008 |
Total IgA (mg/ml) | 295.62 ± 111.48 | 324.71 ± 138.15 | 0.127 |
Alb (g/l) | 24.8 ± 3.98 | 38.99 ± 7.98 | < 0.001 |
C3 (mg/dl) | 92.88 ± 27.70 | 95.97 ± 44.20 | 0.597 |
C4 (mg/dl) | 25.16 ± 8.98 | 26.58 ± 7.48 | 0.475 |
Urine RBC (/ul,median,IQR) | 84 (13 ~ 205) | 12 (5 ~ 34.52) | < 0.001 |
M (M0/M1) | 5/54 | 28/926 | 0.186 |
E (E0/E1) | 14/45 | 627/327 | < 0.001 |
S (S0/S1) | 14/45 | 337/617 | 0.293 |
T (T0/T1/T2) | 8/29/22 | 360/399/195 | < 0.001 |
C (C0/C1/C2) | 8/20/31 | 356/485/113 | < 0.001 |
Clinical and pathological characteristics of patients in IgAN-NS and IgAN-NR groups
Variables | NS group (n = 59) | NR group (n = 57) | P Value |
---|---|---|---|
Age (y) | 42.69 ± 14.96 | 40.67 ± 11.33 | 0.413 |
Gender (M/F) | 26/33 | 28/29 | 0.585 |
SBP (mm Hg) | 124 ± 14 | 130 ± 23 | 0.434 |
HB (g/l) | 120.69 ± 24.73 | 134.9 ± 20.70 | 0.001 |
Scr (umol/l) | 127.34 ± 114.88 | 143.5 ± 86.09 | 0.393 |
eGFR (ml/min.1.73m2) | 68.52 ± 33.04 | 61.58 ± 28.77 | 0.231 |
Proteinuria (g/24 h, median, IQR) | 5160 (4100 ~ 6444) | 5040 (4275 ~ 5770) | 0.557 |
Uric acid (umol/L) | 400.52 ± 107.04 | 438.16 ± 105.07 | 0.062 |
Alb (g/l) | 24.81 ± 3.98 | 34.82 ± 1.16 | < 0.001 |
C3 (mg/dl) | 92.88 ± 27.70 | 95.49 ± 15.5 | 0.555 |
C4 (mg/dl) | 25.16 ± 8.98 | 25.83 ± 7.88 | 0.343 |
Urine RBC (/ul,median,IQR) | 84.78 (17.62 ~ 206.12) | 94.4 (44.12 ~ 206.12) | 0.324 |
TC (mmol/l) | 7.46 ± 2.93 | 5.73 ± 1.54 | 0.02 |
TG (mmol/l) | 2.83 ± 1.89 | 2.74 ± 1.52 | 0.824 |
LDL (mmol/l) | 4.45 ± 1.86 | 3.27 ± 1.16 | 0.02 |
Total IgA (mg/ml) | 295.62 ± 111.48 | 310.38 ± 124.33 | 0.536 |
Total IgG (mg/ml)) | 653.76 ± 224.83 | 894.70 ± 223.73 | < 0.001 |
D-dimer (ng/ml) | 817.94 ± 606.54 | 373.31 ± 274.8 | < 0.001 |
FIB (g/l) | 4.37 ± 1.42 | 3.65 ± 0.53 | 0.003 |
CRP (mg/dl) | 0.54 ± 0.57 | 0.32 ± 0.23 | 0.068 |
Steroid (treatment%) | 57 (96.6%) | 53 (93%) | 0.435 |
Immunosuppressor (treatment%) | 33 (55.9%) | 34 (59.6%) | 0.685 |
The RAS inhibitor (treatment%) | 31 (52.5%) | 27 (47.4%) | 0.401 |
Follow up time (months) | 31.53 ± 28.58 | 29.12 ± 26.66 | 0.641 |
Pathological findings | |||
M (M0/M1) | 5/54 | 2/55 | 0.262 |
E (E0/E1) | 14/45 | 29/28 | 0.002 |
S (S0/S1) | 14/45 | 5/52 | 0.03 |
T (T0/T1/T2) | 8/29/22 | 12/27/18 | 0.593 |
C (C0/C1/C2) | 8/20/31 | 11/29/17 | 0.046 |
Primary outcome analysis
Variables | Univariate analysis | Multivariate analysis | ||
---|---|---|---|---|
OR (95%CI) | P | OR (95%CI) | P | |
Age (y) | 1.006 (0.972–1.041) | 0.752 | ||
eGFR (ml/min.1.73m2) | 0.965 (0.947–0.985) | < 0.001 | 0.980 (0.955–1.005) | 0.119 |
SBP (mm Hg) | 1.062 (1.029–1.096) | < 0.001 | 1.047 (1.009–1.087) | 0.016 |
ALB (g/l) | 0.983 (0.913–1.058) | 0.647 | ||
ALB high group (versus low group) | 0.753 (0.300–1.888) | 0.545 | ||
Uric acid (umol/l) | 1.004 (1.000–1.009) | 0.04 | 1.001 (0.995–1.007) | 0.823 |
TC (mmol/l) | 0.744 (0.511–1.083) | 0.12 | ||
TG (mmol/l) | 0.742 (0.453–1.213) | 0.234 | ||
LDL (mmol/l) | 0.819 (0.535–1.254) | 0.358 | ||
UTP (g/24 h) | 1 (1.000–1.001) | 0.03 | 1 (1.000–1.001) | 0.223 |
M1 (versus M0) | 1.517 (0.174–13.263) | 0.706 | ||
S1 (versus S0) | 0.913 (0.272–3.068) | 0.884 | ||
E1 (versus E0) | 1.872 (0.676–5.187) | 0.228 | ||
T1 + T2 (versusT0) | 3.815 (1.668–8.726) | 0.002 | 2.656 (0.869–8.114) | 0.087 |
C1 + C2 (versus C0) | 2.395 (1.131–5.073) | 0.023 | 1.898 (0.689–5.230) | 0.215 |